Gene · 4300
MLLT3: MLLT3 super elongation complex subunit
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. MLLT3: MLLT3 super elongation complex subunit. Genes, record 4300. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4300
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P42568 | Protein AF-9 | 568 | 26 | Ensembl, GeneID, HGNC |
Source UniProt
Patents19
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 54446 | P42568 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15300 | P42568 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 15300 | P42568 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 15300 | P42568 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 15139 | P42568 | Espacenet |
| US 11845959 B2 | 2023-12-19 | 3 | P42568 | Espacenet |
| US 11564942 B2 | 2023-01-31 | 47 | P42568 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 54071 | P42568 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 157042 | P42568 | Espacenet |
| JP 2021536249 A | 2021-12-27 | 15493 | P42568 | Espacenet |
1 to 10 of 19
See all 19 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,646
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | MLLT3 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 37 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 29 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 22 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 17 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 11 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 10 | 2025 |
| U10CA180886 | COG NCTN Network Group Operations Center - Year 11 STAR Act MCI and PEC Supplement | 10 | 2025 |
| U10CA180899 | Children's Oncology Group Statistics and Data Center | 9 | 2025 |
| P30CA091842 | Cancer Center Support Grant | 7 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 6 | 2025 |
1 to 10 of 1,646Source NIH's project files
See all 1,646 nih grantsPapers2,395
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Transcription pause and elongation regulators mediate somatic hypermutation. | Nature | 2026 | 42816608 | PubTator, text mining | PubMed |
| CD56-Positive Acute Myeloid Leukemia Complicated by Hemophagocytic Lymphohistiocytosis: A case report and narrative review. | Pak J Med Sci | 2026 | 42668947 | PubTator, text mining | PubMed |
| A novel role for transcription factor NFE2 in redox regulation and chemotherapy resistance in acute myeloid leukemia. | Leukemia | 2026 | 42618699 | PubTator, text mining | PubMed |
| Effect of the Proteasome Inhibitor, Bortezomib, on Histone Modifications in Human Leukemic Cell Lines. | Int J Mol Sci | 2026 | 42589252 | PubTator, text mining | PubMed |
| Beyond acetylation: Evaluating the emerging biology of lysine acylation. | Cell Chem Biol | 2026 | 42586062 | PubTator, text mining | PubMed |
| Targeting a CDH1-TK1-dependent DNA Synthesis Pathway Overcomes Chemoresistance in Acute Myeloid Leukemia. | Hematol Oncol | 2026 | 42570285 | PubTator, text mining | PubMed |
| Targeting the PRMT1 axis in cancer: from epigenetic plasticity to contextual therapeutic interventions. | Front Oncol | 2026 | 42523618 | PubTator, text mining | PubMed |
| Context-dependent YEATS-domain inhibition enhances neuronal resilience and improves ALS phenotypes. | Neurobiol Dis | 2026 | 42508735 | PubTator, text mining | PubMed |
| Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming. | Blood | 2026 | 42378254 | PubTator, text mining | PubMed |
| The MLLT3 YEATS domain binds histone marks (H3K9/18/27ac/cr) and ncRNA (7SK), linking transcription and RNA signaling to regulate hematopoiesis. | Cell Rep | 2026 | 42268713 | PubTator, text mining | PubMed |
1 to 10 of 2,395
See all 2,395 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4300
GET https://conductscience.org/api/genes/v1/4300/patents